ClinicalTrials.gg
Not yet recruitingNCT07326631Updated Jan 8, 2026

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

An interventional study of Finerenone in Diabetic Kidney Disease (DKD) and Heart Failure, sponsored by College of Physicians and Surgeons Pakistan. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by College of Physicians and Surgeons Pakistan · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Planned enrollment
5th of 10
120 · median 108
Started
2026
with 4 others
No phase
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
1 of 10
College of Physicians and Surgeons Pakistan

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is the only one with no phase, and was the 7th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

03

Conditions studied

  • Diabetic Kidney Disease (DKD)
  • Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years.
  • Diagnosed cases of type 2 diabetes mellitus.
  • Chronic kidney disease with 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
  • On stable ACE inhibitor or ARB therapy for at least 4 weeks.
  • Serum potassium ≤4.8 mmol/L.
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Symptomatic heart failure ( class II-IV).
  • \<25 mL/min/1.73m² or on maintenance dialysis.
  • Known non-diabetic kidney disease.
  • Recent major cardiovascular event (within 30 days).
  • Serum potassium >4.8 mmol/L or history of severe hyperkalaemia.
  • or to finerenone.
  • Pregnancy or lactation.
  • Any condition limiting compliance or follow-up.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Finerenone Group

    Finerenone Drug

    Drug: Finerenone

Interventions

  • To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Renal Function Decline post finerinone therapy

    Progressive worsening of kidney function is defined as a sustained ≥40% reduction in eGFR from baseline, progression to kidney failure (ESKD), or renal death.

    Time frame: From enrollment to the end of treatment at 06 months

  2. Number of Participants with Heart Failure (HF) Event post finerinone therapy

    Defined as hospitalization for new or worsening heart failure, confirmed by clinical evidence of fluid overload, raised BNP levels and the requirement for intravenous therapy or hemodynamic support.

    Time frame: 6 month

  3. eGFR Measurement

    Estimated glomerular filtration rate calculated using the CKD-EPI formula, standardized for body surface area (mL/min/1.73 m²).

    Time frame: 06 months

  4. Number of Participants with Albuminuria

    Measured as urinary albumin-to-creatinine ratio (UACR), with categories of moderately increased (30-300 mg/g) and severely increased (\>300 mg/g) albuminuria, per KDIGO classification used in the trial protocols.

    Time frame: 06 months

  5. Number of Participants with Hyperkalaemia post treatment

    Defined as a serum potassium level \>5.5 mmol/L, which served as a safety threshold for dose adjustment or discontinuation in the parent trial data.

    Time frame: 06 months

  6. Number of Participants with Cardiovascular (CV) Event post treatment with finerinone therapy

    Includes CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure (HHF) - forming the composite cardiovascular outcome measure in the finerenone studies.

    Time frame: 06 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.

Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 8, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 1, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07326631
Lead sponsor
College of Physicians and Surgeons Pakistan
Responsible party
Muhammad Awais Danish (Dr, Nishtar Medical University) — Principal investigator
First posted
Jan 8, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Muhammad Awais Danish, FCPS (Internal Medicine)
Contact
raoawaisdanish@gmail.com
923037589797

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion